Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_assertion type Assertion NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_head.
- NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_assertion description "[However, the dose of recombinant tissue plasminogen activator for ischemic stroke in Chinese patients should be based on more broad and convincing evidences and randomized trials of lower versus higher doses are needed.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_provenance.
- NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_assertion evidence source_evidence_literature NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_provenance.
- NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_assertion SIO_000772 20224056 NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_provenance.
- NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_assertion wasDerivedFrom befree-2016 NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_provenance.
- NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_assertion wasGeneratedBy ECO_0000203 NP799405.RAgss0adVeNGiaKN36Xa7M-O90lMe9yAaGeKRh_F3eiYI130_provenance.